Last Price$52.14Cboe Previous Close - Real-Time Last Sale as of 4:00PM ET 1/24/20
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$50.40 (100)
Ask (Size)$54.42 (100)
Day Low / HighN/A - N/A
Volume686.4 K

View Pharmaceuticals: Other IndustryPeer Comparison as of 01/24/2020


Zogenix Inc ( NASDAQ )

Price: $52.14
Change: +0.01 (0.02%)
Volume: 686.4 K
4:00PM ET 1/24/2020

Prestige Consumer Healthcare Inc ( NYSE )

Price: $40.88
Change: -0.74 (1.78%)
Volume: 233.4 K
6:30PM ET 1/24/2020

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $12.37
Change: -0.46 (3.59%)
Volume: 2.0 M
4:00PM ET 1/24/2020

Pacira Biosciences Inc ( NASDAQ )

Price: $43.81
Change: -0.13 (0.30%)
Volume: 289.1 K
4:00PM ET 1/24/2020

Corcept Therapeutics Inc ( NASDAQ )

Price: $13.06
Change: -0.08 (0.57%)
Volume: 760.8 K
4:00PM ET 1/24/2020

Read more news Recent News

Zogenix Says Trial Showed Fintepla Reduces Seizure Frequency Caused by Dravet Syndrome
4:43AM ET 12/18/2019 MT Newswires

Zogenix (ZGNX), a biotechnology company, reported Tuesday data from a phase 3 trial of Fintepla in children and young adults with Dravet syndrome, which...

Zogenix's Trial Results of Fintepla in Epilepsy Patients Published in Jama Neurology
4:17PM ET 12/02/2019 MT Newswires

Zogenix (ZGNX) said on Monday JAMA Neurology has published the results of its late-stage trial of its investigational drug, FINTEPLA, in Dravet syndrome...

FDA Accepts Zogenix's New Drug Application For Fintelpa; Shares Gain During Morning Trading
9:55AM ET 11/25/2019 MT Newswires

Zogenix (ZGNX) said Monday that the US Food and Drug Administration accepted the company's New Drug Application for Fintelpa, which is intended to treat...

Analyst Actions: Stifel Cuts Price Target on Zogenix to $70 From $71, Maintains Buy
9:31AM ET 11/08/2019 MT Newswires

Zogenix (ZGNX) has an average rating among analysts of buy, with an average price target of $60. Price: 44.08, Change: +0.53, Percent Change: +1.22 ...

Company Profile

Business DescriptionZogenix, Inc. is a pharmaceutical company. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. View company web site for more details
Address5959 Horton Street
Emeryville, California 94608
Number of Employees90
Recent SEC Filing01/10/20204
President, Chief Executive Officer & DirectorStephen James Farr
CFO, Secretary, Treasurer & Executive VPMichael Patrick Smith
Chief Medical Officer & Executive Vice PresidentBradley S. Galer
Vice President, Legal Council & Compliance OfficeSteven A. Johnson

Company Highlights

Price Open$54.41
Previous Close$52.13
52 Week Range$35.25 - 57.22
Market Capitalization$2.3 B
Shares Outstanding44.3 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement02/27/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.95
Beta vs. S&P 500N/A
Net Profit Margin-22,711.95%
Return on Equity-88.91%

Analyst Ratings as of 10/18/2019

Consensus RecommendationConsensus Icon
Powered by Factset